Clynes, Michael A. http://orcid.org/0000-0001-7597-7658
Parsons, Camille http://orcid.org/0000-0003-3486-8353
Edwards, Mark H. http://orcid.org/0000-0002-8616-3753
Tobias, Jonathan H. http://orcid.org/0000-0002-7475-3932
Deere, Kevin http://orcid.org/0000-0002-9467-0798
Cooper, Cyrus http://orcid.org/0000-0003-3510-0709
Dennison, Elaine M. http://orcid.org/0000-0002-3048-4961
Funding for this research was provided by:
Porticus Foundation (.)
Article History
Received: 12 March 2019
Accepted: 16 April 2019
First Online: 29 April 2019
Compliance with ethical standards
:
: Author Michael Clynes has received support for attending conferences from UCB, Pfizer and Eli Lilly. Author Mark Edwards has received support for attending conferences from Eli Lilly, Pfizer and UCB and support for attending educational courses from Chugai and Abbvie. Author Elaine Dennison has received fees from Pfizer and UCB. Author Professor Cyrus Cooper has received lecture fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB outside of the submitted work. Authors Camille Parsons, Kevin Deere and Jonathan Tobias have nothing to disclose.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: This work was presented as a poster at Rheumatology 2017, Birmingham, UK.